mantle cell lymphoma – media

Dual Therapy of Ibrutinib Plus Venetoclax Improves Results in MCL

Ibrutinib plus venetoclax (ABT-199) improves outcomes over standard therapy in patients with mantle-cell lymphoma (MCL) and a poor prognosis reports a new research in the New England Journal of Medicine.
- Source: MDLinx
- 745
- July 14, 2018
cancer mantle cell lymphoma Researches
FDA approves new treatment for adults with mantle cell lymphoma

The U.S. Food and Drug(FDA) Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.
- Source: Prnewswire
- 784
- November 1, 2017
Calquence FDA mantle cell lymphoma New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.